mGlu7 sleep-wake study featured in Addex Therapeutics (ADXN) Form 6-K filing
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Addex Therapeutics filed a Form 6-K to furnish a press release describing new preclinical research on ADX71743, a selective negative allosteric modulator of metabotropic glutamate receptor 7 (mGlu7). In animal models, ADX71743 increased wakefulness, reduced REM and non-REM sleep, and altered stress-related neurotransmitters.
The findings, published in the International Journal of Neuropsychopharmacology, add to evidence that mGlu7 is a promising target for central nervous system disorders linked to dysregulated stress responses. The report also reiterates key risk disclosures and incorporates the press release by reference into Addex’s existing Form F-3 and Form S-8 registration statements.
Positive
- None.
Negative
- None.
Key Figures
Form type: Form 6-K
Annual Report period: Year ended December 31, 2025
Equity interest in Neurosterix US Holdings LLC: 20% equity interest
+3 more
6 metrics
Form type
Form 6-K
Report of foreign private issuer for July 2026
Annual Report period
Year ended December 31, 2025
Referenced for risk factors in the disclosure
Equity interest in Neurosterix US Holdings LLC
20% equity interest
Described in company overview section
Form F-3 registration number
333-291644
Press release incorporated by reference
Form S-8 registration numbers
333-255124 and 333-272515
Press release incorporated by reference
Report date
July 8, 2026
Date of press release and 6-K signature
Key Terms
negative allosteric modulator, metabotropic glutamate receptor 7, central nervous system disorders, post-traumatic stress disorder (PTSD), +2 more
6 terms
negative allosteric modulator medical
"ADX71743, a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7)"
A negative allosteric modulator is a drug or compound that binds to a site on a biological receptor different from where the body's natural molecule binds, and reduces the receptor's activity. Think of it as turning down the volume on a signal without cutting it off entirely. For investors, this mechanism can mean more selective effects, potentially fewer side effects, and distinct commercial and regulatory prospects compared with drugs that fully block or mimic a receptor.
metabotropic glutamate receptor 7 medical
"a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7)"
central nervous system disorders medical
"a promising therapeutic target across a range of central nervous system disorders"
Conditions that affect the brain and spinal cord, such as diseases that disrupt thinking, movement, sensation or mood, are grouped as central nervous system (CNS) disorders. Investors watch them because they represent large, persistent medical needs and potential markets for drugs, devices and therapies; like underserved neighborhoods waiting for new infrastructure, successful treatments can create steady revenue streams or sharply alter a company’s prospects.
post-traumatic stress disorder (PTSD) medical
"including mood disorders, anxiety disorders, post-traumatic stress disorder (PTSD)"
A mental health condition that can develop after exposure to a terrifying or life-threatening event, causing persistent distressing memories, heightened anxiety, sleep disturbance, and avoidance of reminders. For investors, PTSD matters because it drives demand for treatments, shapes regulatory and insurance coverage decisions for new therapies, and can influence workforce productivity and legal or disability costs—essentially acting as a market signal of medical need and potential revenue for related products.
allosteric modulators medical
"developing a portfolio of novel small molecule allosteric modulators for neurological disorders"
Allosteric modulators are molecules that bind to a spot on a protein that is separate from the protein’s main active site and change how strongly the protein responds to its normal signals—like a dimmer switch that adjusts light instead of turning it fully on or off. For investors, they matter because this approach can yield drugs that are more selective, have fewer side effects, and offer novel patentable mechanisms, which can improve clinical success and commercial value.
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What does Addex Therapeutics (ADXN) report in this Form 6-K?
Addex reports the publication of new preclinical research on ADX71743, a selective mGlu7 negative allosteric modulator. The study in animal models links mGlu7 modulation to sleep-wake regulation and stress-related neurochemistry, supporting its potential relevance in central nervous system disorders.
What is ADX71743 in the Addex Therapeutics (ADXN) pipeline?
ADX71743 is a potent, selective, brain-penetrant negative allosteric modulator of mGlu7. It serves as a prototype molecule in numerous studies exploring mGlu7’s therapeutic potential in anxiety, stress-related disorders, sleep regulation, fear memory, and visceral pain, and is part of a broader mGlu7 program.
How did ADX71743 affect sleep and stress markers in the reported study?
In rats, ADX71743 increased wakefulness and reduced both REM and non-REM sleep. It also modified stress-induced changes in neurotransmitters such as glutamate, GABA, and monoamines across several brain regions, consistent with modulation of stress-responsive neural circuits in vivo.
Which disorders could mGlu7 modulation potentially address according to Addex (ADXN)?
The research supports mGlu7 as a potential target across central nervous system disorders involving dysregulated stress responses. These include mood and anxiety disorders, post-traumatic stress disorder (PTSD), and other conditions where stress-related neural circuits and sleep-wake regulation are clinically relevant.
What other programs does Addex Therapeutics (ADXN) highlight in this disclosure?
Addex describes its lead candidate dipraglurant, an mGlu5 negative allosteric modulator for brain injury recovery. It also notes partnered and internal GABAB PAM programs, equity interest in Neurosterix US Holdings LLC, and an investment in Stalicla for precision neurodevelopmental and neuropsychiatric medicine.
How is Neurosterix involved with Addex Therapeutics’ mGlu7 program?
Neurosterix, launched by Addex and Perceptive Advisors in 2024, is advancing the mGlu7 program that includes ADX71743. Addex holds a 20% equity interest in Neurosterix US Holdings LLC, which develops multiple allosteric modulator programs for psychiatric and mood-related indications.